Company intelligence / Profile preview

FlowSense

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

FlowSense is the world's first patented, non-invasive period blood detection device designed specifically for visually impaired women. The device uses vibration and audio cues to detect menstrual bleeding and track menstrual cycles. The company addresses critical health risks affecting approximately 660 million visually impaired women globally, including infections and toxic shock syndrome from pad overuse.

Therapeutic areas: Women's Health
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on FlowSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FlowSense.

Explore the full profile